Psilocybin lowered inflammation and a marker of mitochondrial stress in people with Parkinson's — early human data

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Parkinson's disease is characterised by dysregulated inflammation and mitochondrial dysfunction, yet people with neurodegenerative conditions are usually excluded from psychedelic trials over safety concerns. The UCSF team's original pilot — 12 participants given psilocybin to test feasibility and safety — found a reassuring safety profile. This new analysis asked what happened to their inflammatory and mitochondrial-stress markers.

What changed in the blood after psilocybin?

The team measured five signalling molecules involved in inflammation before and after two psilocybin sessions. Participants had significantly lower inflammation levels than baseline, and the changes persisted a month after the final dose. A blood marker of mitochondrial stress also improved substantially immediately after treatment — though that improvement did not hold at the longer-term follow-up.

Why would a serotonin drug touch mitochondria at all?

Classic psychedelics bind 5-HT2A serotonin receptors, which are found on cells well beyond the brain. Lab and animal work over roughly fifteen years — including LSU pharmacologist Charles Nichols's programme — has found anti-inflammatory and mitochondrial-protective effects at those receptors. Co-author D. Parker Kelley of Columbia's Mitochondrial PsychoBiology group frames the human data as a potential jumping-off point for Parkinson's, neuropsychiatric and even cardio-metabolic and inflammatory disorders.

What are the limits of this signal?

Real ones, stated by the researchers themselves: 12 participants, no control group, no blinding — everyone knew they were receiving psilocybin, so expectation and time effects cannot be separated from drug effects. Co-author Aoife O'Donovan emphasises the biomarker changes need confirmation in follow-up controlled studies before any definitive claims. This is first-in-patients biological evidence that a long lab story may hold in humans — nothing more, and nothing less.

Where the evidence stands

• Established: Parkinson's disease involves inflammation and mitochondrial dysfunction; psychedelics acting at 5-HT2A receptors have shown anti-inflammatory and mitochondrial-protective effects in cell and animal models.
• Preliminary: In 12 people with Parkinson's (JAMA Psychiatry, reported Oct 21, 2026), two psilocybin sessions were followed by significantly lower levels of five inflammatory markers persisting at one month, and a substantial short-term improvement in a blood marker of mitochondrial stress that did not persist at longer follow-up; the study was small and uncontrolled.
• Absent: Controlled, blinded evidence that psilocybin improves inflammation, mitochondrial function, symptoms or disease course in Parkinson's or any other condition.